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Abstract 
Rectal mucosa-associated lymphoid tissue (MALT) lymphoma is a rare condition. Although 
the majority of patients undergo surgical resection, a definitive treatment for rectal MALT 
lymphoma has not yet been established. In the present study, we report the outcome of 
radiotherapy in 3 patients with rectal MALT lymphoma. Our cohort ranged from 56 to 
65 years of age. The male/female ratio was 1:2, and all patients were in stage I (Lugano 
classification) of the disease. Endoscopic findings revealed elevated lesions resembling 
submucosal tumors in 2 patients, and a sessile elevated lesion with a nodular surface in 
1 patient. One of the 3 patients underwent magnifying endoscopy with crystal violet staining 
that demonstrated a type I pit pattern (Kudo’s classification) lesion with a broad intervening 
area caused by the upthrust of the tumor from the submucosa. All patients tolerated 
radiotherapy at doses of 30 Gy without major complications and achieved complete 
remission. Follow-up ranged from 13 to 75 months (mean 51.0 months), revealing no 
recurrence of MALT lymphoma. As such, we propose radiotherapy to be a safe and effective 
means for treating rectal MALT lymphoma. 
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Introduction 
Mucosa-associated lymphoid tissue (MALT) lymphoma was first described 
histologically by Isaacson and Wright in 1983 [1] and is now classified as an 
extranodal marginal zone B cell lymphoma of MALT type according to the World 
Health Organization classification. MALT lymphoma develops in diverse anatomic 
locations including the stomach, salivary gland, thyroid, lung, and breast. However, 
rectal involvement is extremely rare. 
Current therapeutic options for rectal MALT lymphomas include surgical resection, 
endoscopic mucosal resection (EMR), antibiotic therapy (including Helicobacter pylori 
eradication), chemotherapy and radiotherapy. Since H. pylori infection plays an 
important role in the development of gastric MALT lymphoma, its eradication has 
become a first-line therapy for this disease. On the other hand, although the majority of 
early patients with rectal MALT lymphoma undergo surgical resection, a definitive 
treatment for rectal MALT lymphoma has not yet been established. 
We here report 3 patients with H. pylori-negative primary rectal MALT lymphoma 
who achieved complete remission (CR) by radiotherapy, and review the existing 
literature on this treatment. 
Case Reports 
Patient 1 
A 62-year-old woman underwent colonoscopy for further examination of occult blood in the 
stool. Colonoscopic examination revealed two elevated lesions 6 and 20 mm in diameter that 
resembled submucosal tumors in the lower rectum (fig. 1a). Magnifying endoscopy with crystal 
violet staining showed a type I pit pattern (Kudo’s classification [2]) with a broad intervening area 
caused by the upthrust of the tumor from the submucosa (fig. 1b). Endoscopic ultrasonography 
showed a hypoechoic mass at the second and third layers (fig. 2a). Barium enema X-ray examination 
revealed an elevated lesion 20 mm in diameter in the lower rectum (fig. 2b). Histopathological 
examination of rectal biopsy specimens showed a diffuse proliferation of lymphoid cells of 
intermediate size with an irregular cleaved nucleus and moderate cytoplasm (centrocyte-like cells) 
(fig. 3a, b). Immunohistochemistry showed that the neoplastic cells were positive for CD20 (fig. 3c) 
but negative for CD3 (fig. 3d), CD5 and CD10. Neither B cell monoclonality nor the API2-MALT1 fusion 
gene were detected. No extraintestinal involvement was found on staging elevation, which included 
capsule endoscopy, double balloon enteroscopy, computed tomography, fluorodeoxyglucose positron 
emission tomography and bone marrow biopsy. Based on these findings, the diagnosis of stage I rectal 
MALT lymphoma (Lugano classification) was made. She had no weight loss, fever or night sweats. 
No lymphadenopathy was detected, and serum levels of soluble interleukin-2 receptor and beta2 
microglobulin were within normal ranges. Upper gastrointestinal endoscopy revealed no abnormal 
findings and H. pylori was not detected in gastric biopsy specimens or biopsy specimen cultures. We 
therefore performed radiotherapy (total dose: 30 Gy/20 fr), at the end of which colonoscopy revealed 
that the elevated lesions had disappeared and the site showed white scars (fig. 1c). Biopsy specimens 
demonstrated that small lymphocytes had decreased and the centrocyte-like cells had almost 
disappeared. Achievement of CR was confirmed by colonoscopic and histologic examinations. She has 
had no relapse in 13 months since radiotherapy. 
Patient 2 
A 65-year-old man underwent colonoscopy for further examination of a positive fecal occult 
blood test. He had undergone total gastrectomy for gastric cancer 5 years prior. Colonoscopic 
examination revealed an elevated lesion 10 mm in diameter with telangiectasia that resembled 
submucosal tumor in the lower rectum. Histopathological examination of rectal biopsy specimens 
showed a diffuse proliferation of centrocyte-like cells and glandular destruction with centrocyte-like  
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cells (lymphoepithelial lesions), and the proliferating cells were phenotypically characterized as 
CD20+, CD3–, CD5– and bcl-2± by immunohistochemical staging. Stage I rectal MALT lymphoma 
(Lugano classification) was diagnosed. The API2-MALT1 fusion gene was not detected, but B cell 
monoclonality was noted. Examination for serum H. pylori IgG antibody was negative. We performed 
radiotherapy (total dose: 30 Gy/20 fr), at the end of which colonoscopy revealed that the elevated 
lesion had disappeared. CR was confirmed by colonoscopic and histologic examinations 1 month 
following treatment. Afterwards, the patient was followed closely by colonoscopy, but no relapse has 
been detected after 65 months. 
Patient 3 
A 56-year-old woman underwent colonoscopy due to hematochezia, which revealed a sessile 
elevated lesion 25 mm in diameter with a nodular surface in the upper rectum and a small elevated 
lesion 10 mm in diameter in the lower rectum. Although biopsy specimens showed diffuse 
proliferation of small atypical lymphocytes, it was difficult to distinguish MALT lymphoma from 
reactive lymphoreticular hyperplasia. EMR was performed on the sessile lesion to clarify the 
diagnosis. EMR specimens showed colonic mucosa with marked expansion of the lamina propria by 
centrocyte-like cells. Admixed were mature lymphocytes and plasma cells. Immunohistochemistry 
showed that the neoplastic cells were positive for CD20 and bcl-2, but negative for CD3, CD5, CD10 
and cyclin D1. She was diagnosed as having stage I rectal MALT lymphoma (Lugano classification). 
Neither B cell monoclonality nor the API2-MALT1 fusion gene were detected. Upper gastrointestinal 
endoscopy revealed no abnormal findings and H. pylori was not detected in gastric biopsy specimens 
or biopsy specimen cultures. We administered radiotherapy (total dose: 30 Gy/20 fr). Following 
treatment, colonoscopy revealed an EMR scar in the upper rectum and the absence of elevated lesion 
in the lower rectum. CR was confirmed by colonoscopic and histologic examinations. No relapse has 
been detected in 75 months. 
Discussion 
MALT lymphomas were first described histologically by Isaacson and Wright 
in 1983 [1] as diffuse infiltration of small lymphoid cells (centrocyte-like or 
monocytoid-looking cells), infiltration of lymphoma cells around the epithelium 
(lymphoepithelial lesions) and proliferation of plasma cells in the lamina propria of 
the mucosa. However, lymphoepithelial lesions are found with low frequency in 
colorectal MALT lymphomas. Primary colorectal lymphomas account for only about 
0.2% of large intestinal malignancies, of which MALT lymphoma is the most common. 
Colorectal MALT lymphoma was most frequently found in the rectum [3]. Since rectal 
MALT lymphoma is very rare, its treatment has not been well investigated compared 
to that of gastric MALT lymphoma. Reported therapeutic options for rectal MALT 
lymphoma include surgical resection [4], EMR [4], H. pylori eradication [5, 6], 
chemotherapy [7] and radiotherapy. 
Since MALT lymphoma tends to remain localized, the majority of early patients 
underwent surgical resection. However, as abdominoperineal resections were almost 
always necessary, patients’ quality of life decreased following construction of an 
artificial anus. Some authors reported that EMR was useful for obtaining an accurate 
diagnosis [8]. Yet both the frequency of lymph node metastasis and the need for 
lymphadenectomy are not well known, and thus adoption of EMR as a therapeutic 
treatment is unreliable. Chemotherapy is not recommended for patients with localized 
MALT lymphomas as these tumors are less responsive to standard chemotherapy than 
aggressive lymphomas [9, 10]. 
H. pylori infection plays an important role in the development of gastric MALT 
lymphoma, and its eradication has become a first-line therapy for this disease. Several  
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authors have performed antibiotic therapy on rectal MALT lymphoma patients 
regardless of H. pylori infection status and achieved CR [5, 6]. These reports suggested 
that the efficacy of eradication was not related with regression of rectal MALT 
lymphoma; namely, the development of rectal MALT lymphoma was due less to 
H. pylori infection and more to other microorganisms. This hypothesis remains 
unproven, however, and the rate of remission for antibiotic therapy has not been well 
investigated. Of the 16 reported patients with extragastric MALT lymphoma with 
H. pylori infection who underwent eradication, only one patient achieved regression, 
and the author suggested that antibiotic treatment targeting H. pylori should be 
discouraged in patients with extragastric MALT lymphomas [11]. In addition, the time 
to remission varies for this treatment; although one study reported that the median 
time to remission for colonic MALT lymphoma was 5.5 months [5], the schedule to 
evaluate treatment response and the timing of secondary treatment have not been 
determined. Antibiotic therapy may be attempted for patients with rectal MALT 
lymphoma regardless of H. pylori infection status before other treatment courses, but 
further studies on the efficacy of antibiotic therapy for rectal MALT lymphoma are 
warranted. 
The radiosensitivity of MALT is well established, and radiotherapy has been found 
to be highly effective in controlling localized MALT lymphomas [9]. A total dose of 
30 Gy is standard for the treatment of gastric MALT lymphoma. Other reports have 
suggested that 30 Gy/20 fr was appropriate for controlling extragastric MALT 
lymphomas without severe detrimental effects or serious local failure, particularly if 
the radiotherapy dose was less than 30 Gy [9, 10]. As toxicity after radiotherapy is 
related to total dose, radiation courses of 60–70 Gy may damage the intestinal tract 
[12]. Additionally, some authors have reported premature ovarian failure after 
radiotherapy (total dose: 30 Gy) [13]. Although the fertility of the patient must be 
considered, it is accepted that a total dose of 30 Gy is effective and safe. 
We scanned the PubMed database for English language articles dated from 1973 to 
2010 using the terms ‘rectum’ or ‘colon’, ‘MALT’ and ‘radiotherapy’. Only 4 published 
cases of primary rectal MALT lymphoma treated with radiotherapy were found 
[9, 10, 14, 15], which are summarized along with our patients in table 1. Patient age 
ranged from 26 to 65 years (mean 53.8 years). The male/female ratio was 3:2. 
Endoscopic findings were elevated lesions resembling submucosal tumors in 4 patients. 
One patient had a sessile elevated lesion. All patients were in stage I (Lugano 
classification) of the disease at the time of diagnosis. API2-MALT1 fusion genes were 
not detected in any case. Although all patients were H. pylori-negative, eradication was 
performed on one patient. The patient’s tumor diameter was long. The median 
radiation dose was 34.3 Gy (range 30–45 Gy). All patients tolerated the radiotherapy 
well with little acute toxicity. Follow-up ranged from 13 to 75 months (mean 
44.3 months), revealing CR in 6 patients (85.7%). All patients who achieved CR had no 
recurrence of the disease. 
In conclusion, our results and those of previous reports suggest that radiotherapy at 
a total dose of 30 Gy is both effective and safe for treatment of rectal MALT lymphoma. 
Further studies are needed to determine the role of microorganisms in this disease and 
the possible merits of combined radiotherapy and antibiotic therapy.  
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Table 1. Summary of primary rectal MALT lymphoma cases treated by radiotherapy reported in the 
English language literature 
                         
                         
First author 
[reference] 
Year  Age, 
years 
Sex  Symptoms  Endoscopic findings  Stage  
(Lugano 
classification) 
API2-
MALT1 
fusion gene 
HP  Eradi-
cation 
Radio-
therapy 
dose, Gy 
Out-
come 
<Follow- 
<up,  
<months 
                         
                         
Tsang [10]  2003  ND  ND  ND  ND  I  ND  ND  ND  35  ND  >48 
Yamashita [9]  2008  ND  ND  ND  ND  ND  ND  ND  ND  30  CR  <ND 
Kobayashi [14]  2008  26  M  abdominal fullness  hemorrhagic submucosal 
tumor lesions 
I  –  –  +  40  CR  <24 
Foo [15]  2008  60  M  constipation with  
subsequent rectal  
bleeding  
large rectal tumor  I  ND  –  –  45  CR  <41 
Our report                         
Case 1    62  F  occult stool blood 
positive 
elevated submucosal tumor 
lesions 
I  –  –  –  30  CR  <13 
Case 2    65  M  occult stool blood 
positive 
an elevated submucosal 
tumor lesion 
I  –  –  –  30  CR  <65 
Case 3    56  F  hematochezia  sessile elevated lesion and 
small elevated lesion 
I  –  –  –  30  CR  <75 
                         
                         
HP = Helicobacter pylori; ND = not described; M = male; F = female; CR = complete remission. 
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Fig. 1. a Colonoscopy revealed two lesions resembling submucosal tumors in the lower rectum. 
b Magnifying endoscopy with crystal violet staining of the box in a showed a type I pit pattern with a 
broad intervening area. c Colonoscopy after radiotherapy showed that the tumors had disappeared, 
and the site shows white scars. 
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Fig. 2. a Endoscopic ultrasonography showed a hypoechoic mass at the second and third layers 
(arrows). b Barium enema X-ray examination showed an elevated lesion in the lower rectum 
(arrows). 
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Fig. 3. a Microscopic findings of a rectal biopsy specimen showed diffuse proliferation of 
centrocyte-like cells (HE staining, original magnification ×20). b High-power magnification of a 
(HE staining, original magnification ×100). c CD20 immunohistochemical staining (original 
magnification ×20). d CD3 immunohistochemical staining (original magnification ×20). 
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